Skip to main content
Top
Published in: Diabetologia 12/2007

01-12-2007 | Article

Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes

Authors: E. S. Kilpatrick, A. S. Rigby, K. Goode, S. L. Atkin

Published in: Diabetologia | Issue 12/2007

Login to get access

Abstract

Aims/hypothesis

The main disadvantage of intensive treatment in the Diabetes Control and Complications Trial (DCCT) was an increased risk of hypoglycaemia that was not explained by the difference in HbA1c values alone. This study re-analysed DCCT data to establish whether mean blood glucose (MBG) and/or glucose variability add to the predictive value of HbA1c for hypoglycaemia risk in type 1 diabetes.

Methods

The times to first and subsequent severe hypoglycaemic events were compared with MBG, HbA1c and within-day SD of blood glucose using Cox regression after adjusting for other known risk factors for hypoglycaemia.

Results

On its own, the incidence of time to first hypoglycaemic event increased 1.05-fold for each 1 mmol/l decrease in MBG and 1.07-fold for every 1 mmol/l increase in glucose SD. MBG and SD of blood glucose also both added to the ability of HbA1c to predict repeated hypoglycaemic events: after adjusting for HbA1c, a 1 mmol/l increase in SD was associated with a 1.09-fold increased risk of a first event, increasing to a 1.12-fold risk of a fifth event. A 1 mmol/l fall in MBG added a constant 1.02–1.03-fold risk of repeated events. Daytime events were predicted more accurately than nocturnal episodes.

Conclusions/interpretation

This study has established that HbA1c, MBG and glucose variability measurements each have an independent role in determining an individual’s risk of hypoglycaemia in type 1 diabetes. All three aspects of glycaemic assessment should thus be considered in patients in whom hypoglycaemia is a real or potential problem.
Literature
1.
go back to reference The Diabetes Control and Complications Trial Research Group (1987) Diabetes Control and Complications Trial (DCCT): results of feasibility study. Diabetes Care 10:1–19CrossRef The Diabetes Control and Complications Trial Research Group (1987) Diabetes Control and Complications Trial (DCCT): results of feasibility study. Diabetes Care 10:1–19CrossRef
2.
go back to reference The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
3.
go back to reference The Diabetes Control and Complications Trial Research Group (1995) The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44:968–983CrossRef The Diabetes Control and Complications Trial Research Group (1995) The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44:968–983CrossRef
4.
go back to reference UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853CrossRef
5.
go back to reference Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCrossRef Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCrossRef
6.
go back to reference The Diabetes Control and Complications Trial Research Group (1996) The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289–1298CrossRef The Diabetes Control and Complications Trial Research Group (1996) The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289–1298CrossRef
7.
8.
go back to reference MacLeod KM, Hepburn DA, Frier BM (1993) Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 10:238–245PubMedCrossRef MacLeod KM, Hepburn DA, Frier BM (1993) Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 10:238–245PubMedCrossRef
9.
go back to reference Laing SP, Swerdlow AJ, Slater SD et al (1999) The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 16:466–471PubMedCrossRef Laing SP, Swerdlow AJ, Slater SD et al (1999) The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 16:466–471PubMedCrossRef
10.
go back to reference Cox DJ, Penberthy JK, Zrebiec J et al (2003) Diabetes and driving mishaps: frequency and correlations from a multinational survey. Diabetes Care 26:2329–2334PubMedCrossRef Cox DJ, Penberthy JK, Zrebiec J et al (2003) Diabetes and driving mishaps: frequency and correlations from a multinational survey. Diabetes Care 26:2329–2334PubMedCrossRef
11.
go back to reference The Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 46:271–286CrossRef The Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 46:271–286CrossRef
12.
go back to reference Rohlfing CL, Wiedmeyer HM, Little RR et al (2002) Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the diabetes control and complications trial. Diabetes Care 25:275–278PubMedCrossRef Rohlfing CL, Wiedmeyer HM, Little RR et al (2002) Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the diabetes control and complications trial. Diabetes Care 25:275–278PubMedCrossRef
13.
go back to reference American Diabetes Association Workgroup on Hypoglycemia (2005) Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 28:1245–1249CrossRef American Diabetes Association Workgroup on Hypoglycemia (2005) Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 28:1245–1249CrossRef
14.
go back to reference The Diabetes Control and Complications Trial Research Group (1991) Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 90:450–459 The Diabetes Control and Complications Trial Research Group (1991) Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 90:450–459
15.
go back to reference Tai MM (1994) A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 17:152–154PubMedCrossRef Tai MM (1994) A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 17:152–154PubMedCrossRef
16.
go back to reference Moberg E, Kollind M, Lins PE, Adamson U (1993) Estimation of blood-glucose variability in patients with insulin-dependent diabetes mellitus. Scand J Clin Lab Invest 53:507–514PubMed Moberg E, Kollind M, Lins PE, Adamson U (1993) Estimation of blood-glucose variability in patients with insulin-dependent diabetes mellitus. Scand J Clin Lab Invest 53:507–514PubMed
17.
go back to reference Service FJ, Molnar GD, Rosevear JW et al (1970) Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19:644–655PubMed Service FJ, Molnar GD, Rosevear JW et al (1970) Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19:644–655PubMed
18.
go back to reference Wang D, Bakhai A (2006) Clinical Trials. A practical guide to design, analysis and reporting. Remedica, London Wang D, Bakhai A (2006) Clinical Trials. A practical guide to design, analysis and reporting. Remedica, London
19.
go back to reference Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 26:881–885PubMedCrossRef Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 26:881–885PubMedCrossRef
20.
go back to reference Schoenfeld D (1982) Partial residual estimation for the proportional hazards regression model. Biometrika 69:239–241CrossRef Schoenfeld D (1982) Partial residual estimation for the proportional hazards regression model. Biometrika 69:239–241CrossRef
21.
go back to reference Grambsch P, Therneau TM (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515–526CrossRef Grambsch P, Therneau TM (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515–526CrossRef
22.
go back to reference Francis B, Green M, Payne M (1994) The GLIM System. Release 4 manual. Clarendon, Oxford Francis B, Green M, Payne M (1994) The GLIM System. Release 4 manual. Clarendon, Oxford
23.
go back to reference Lawless JFW, Wigg MB, Tuli S, Drake J, Lamberti-Pasculli M. (2001) Analysis of repeated failures or durations, with application to shunt failures for patients with paediatric hydrocephalus. Applied Statistician 50:449–465 Lawless JFW, Wigg MB, Tuli S, Drake J, Lamberti-Pasculli M. (2001) Analysis of repeated failures or durations, with application to shunt failures for patients with paediatric hydrocephalus. Applied Statistician 50:449–465
24.
go back to reference Fine JP (1999) Analysing competing risks data with transformation models. J R Stat Soc Ser B 61:817–830CrossRef Fine JP (1999) Analysing competing risks data with transformation models. J R Stat Soc Ser B 61:817–830CrossRef
25.
26.
go back to reference Efron B (2000) The bootstrap and modern statistics. J Am Stat Assoc 95:1293–1296CrossRef Efron B (2000) The bootstrap and modern statistics. J Am Stat Assoc 95:1293–1296CrossRef
27.
go back to reference Efron B, Tibshirani R (1986) Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1:54–77 Efron B, Tibshirani R (1986) Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1:54–77
28.
go back to reference Sauerbrei W, Schumacher M (1992) A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11:2093–2109PubMedCrossRef Sauerbrei W, Schumacher M (1992) A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11:2093–2109PubMedCrossRef
29.
go back to reference Kilpatrick ES, Rigby AS, Atkin SL (2006) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486–1490PubMedCrossRef Kilpatrick ES, Rigby AS, Atkin SL (2006) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486–1490PubMedCrossRef
31.
go back to reference Goldgewicht C, Slama G, Papoz L, Tchobroutsky G (1983) Hypoglycaemic reactions in 172 Type 1 (insulin-dependent) diabetic patients. Diabetologia 24:95–99PubMedCrossRef Goldgewicht C, Slama G, Papoz L, Tchobroutsky G (1983) Hypoglycaemic reactions in 172 Type 1 (insulin-dependent) diabetic patients. Diabetologia 24:95–99PubMedCrossRef
32.
go back to reference ter Braak E, Appelman A, van de Laak M et al (2000) Clinical characteristics of type 1 diabetic patients with and without severe hypoglycaemia. Diabetes Care 23:1467–1471PubMedCrossRef ter Braak E, Appelman A, van de Laak M et al (2000) Clinical characteristics of type 1 diabetic patients with and without severe hypoglycaemia. Diabetes Care 23:1467–1471PubMedCrossRef
33.
go back to reference Kilpatrick ES, Rigby AS, Atkin SL (2007) Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clin Chem 53:897–901PubMedCrossRef Kilpatrick ES, Rigby AS, Atkin SL (2007) Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clin Chem 53:897–901PubMedCrossRef
34.
go back to reference Pedersen-Bjergaard U, Pramming S, Heller SR et al (2004) Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev 20:479–486PubMedCrossRef Pedersen-Bjergaard U, Pramming S, Heller SR et al (2004) Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev 20:479–486PubMedCrossRef
35.
go back to reference American Diabetes Association (2007) Standards of Medical Care in Diabetes—2007. Diabetes Care 30:S4–S41CrossRef American Diabetes Association (2007) Standards of Medical Care in Diabetes—2007. Diabetes Care 30:S4–S41CrossRef
36.
go back to reference Kovatchev BP, Cox DJ, Gonder-Frederick L, Clarke WL (2002) Methods for quantifying self-monitoring blood glucose profiles exemplified by an examination of blood glucose patterns in patients with type 1 and type 2 diabetes. Diabetes Technol Ther 4:295–303PubMedCrossRef Kovatchev BP, Cox DJ, Gonder-Frederick L, Clarke WL (2002) Methods for quantifying self-monitoring blood glucose profiles exemplified by an examination of blood glucose patterns in patients with type 1 and type 2 diabetes. Diabetes Technol Ther 4:295–303PubMedCrossRef
37.
go back to reference Kovatchev BP, Cox DJ, Kumar A, Gonder-Frederick L, Clarke WL (2003) Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther 5:817–828PubMedCrossRef Kovatchev BP, Cox DJ, Kumar A, Gonder-Frederick L, Clarke WL (2003) Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther 5:817–828PubMedCrossRef
38.
go back to reference Klonoff DC (2005) Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 28:1231–1239PubMedCrossRef Klonoff DC (2005) Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 28:1231–1239PubMedCrossRef
39.
go back to reference Garg S, Zisser H, Schwartz S et al (2006) Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 29:44–50PubMedCrossRef Garg S, Zisser H, Schwartz S et al (2006) Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 29:44–50PubMedCrossRef
40.
go back to reference Boland E, Monsod T, Delucia M et al (2001) Limitations of conventional methods of self-monitoring of blood glucose: Lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 24:1858–1862PubMedCrossRef Boland E, Monsod T, Delucia M et al (2001) Limitations of conventional methods of self-monitoring of blood glucose: Lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 24:1858–1862PubMedCrossRef
Metadata
Title
Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes
Authors
E. S. Kilpatrick
A. S. Rigby
K. Goode
S. L. Atkin
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0820-z

Other articles of this Issue 12/2007

Diabetologia 12/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.